Study calls for healthy longevity medicine during early development
Scientists propose the PROSPER consortium to introduce healthy longevity medicine at the earliest life stages
An international team of researchers proposed that longevity interventions and research should begin at the earliest ages possible, including before birth, to prevent age-related decline effectively. The scientists presented their case for a life-course consortium dedicated to healthy longevity medicine in a correspondence paper published in Nature Health on Friday. The proposed initiative, named PROSPER, stands for Pregestational and Pediatric Research for Optimal Healthspan and Early-life Resilience.
Nature Health reported that the researchers are advocating for this shift because the majority of current healthy longevity medicine focuses almost entirely on adult populations. Under existing models, clinical interventions are typically introduced only after decades of accumulated molecular and cellular damage have already occurred. The authors argued that this conventional approach overlooks a critical window of opportunity during early human development.
The paper highlighted that whilst previous studies have investigated how childhood factors influence lifespan, the scientific community lacks cohesive frameworks to assess ageing markers across an entire lifetime. Furthermore, the experts noted that standard biological markers used to measure ageing in adults cannot be applied to children. At earlier stages of life, these markers reflect developmental synchrony and resilience rather than cumulative bodily damage, necessitating entirely new age-specific models and diagnostic systems.
The PROSPER initiative aims to systematically integrate multiomics data, clinical phenotypes, and functional measures across various developmental stages. This collective data will allow scientists to construct longitudinal biological trajectories to predict health risks and optimise functional "peakspan"—the period of life when an individual is at peak performance. Ultimately, the consortium hopes to establish age-specific diagnostic and therapeutic guidelines that can be seamlessly embedded into routine obstetric and paediatric medical care.